Indus Biotech Paradigm

The biggest issue confronting drug discovery today is the exorbitant cost and lengthy time to market. This is largely due to the need to “load” the cost of numerous failures along the pathway to achieving a single NDA, with failures often happening at very late stages of clinical development and causing a huge cost and time setback.

As against the existing paradigm, the innovative discovery methodology adopted by Indus Biotech Private Limited significantly reduces time and cost to markets, to a fraction, due to avoidance of expensive failures.

This can be ascribed to several factors in the Company’s discovery process, as described below:

1. The drug candidates are developed from food chain raw materials that have existing evidence of physiological activity.
2. The Company has developed a proprietary platform technology for separation and isolation of molecules by molecular partitioning, wherein each drug candidate is novel and protected by IPR.
3. Based on rational drug design with retro pharmacology, all isolated molecules are screened in animal models for specific diseases. This method obviates the need for mass screening and reduces pre-clinical development cost. More importantly, it established the molecule-disease link.
4. After confirming efficacy and safety in pre-clinical stage, the drug candidates are tested for safety and efficacy in “proof-of-concept clinical trials” in humans. These VERY early clinical studies are possible because of Indus Biotech’s selection of food chain raw materials as the starting point. Commonly used by populations for centuries, such drug candidates are inherently safe for human consumption. The above facts offer opportunity for human trials as food supplements. Indus Biotech uses this facility to conduct relevant and early “proof-of-concept” studies and thus mitigates risk of failure in the future.

Indus Drug Discovery & Development Process